Back to top
more

Aduro Biotech, Inc. (ADRO)

(Delayed Data from NSDQ)

$4.26 USD

4.26
328,546

+0.11 (2.65%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.27 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Aduro (ADRO) Earnings Miss in Q2, Revenues Meet Estimates

by Zacks Equity Research

Aduro (ADRO) suffers wider-than-expected loss in the second quarter while revenues match estimates.

Aduro Biotech (ADRO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Aduro Biotech (ADRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio

by Zacks Equity Research

AbbVie (ABBV) buys Mavupharma to develop novel treatments for cancer using the latter's STING signaling pathway.

Aduro Stock Crashes After ASCO Updates on Cancer Candidate

by Zacks Equity Research

Aduro (ADRO) presents updated data from an ongoing phase Ib study evaluating its STING agonist, ADU-S100 in combination with Novartis' checkpoint inhibitor.

Aduro (ADRO) Q1 Earnings and Revenues Fall Shy of Estimates

by Zacks Equity Research

Aduro (ADRO) suspends the BION-1301 program for MM in Q1 due to severe competition.

Aduro Biotech (ADRO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Aduro Biotech (ADRO) delivered earnings and revenue surprises of -70.59% and -51.23%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Axsome (AXSM) This Earnings Season?

by Zacks Equity Research

On Axsome's (AXSM) first-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.

Guardant Health (GH) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

At Guardant Health's (GH) Q1 conference, investors will watch out for the updates on liquid biopsy-based Guardant360 and GuardantOMNI tests that could help detect advanced stages of cancer.

Proteostasis (PTI) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

During Proteostasis' (PTI) Q1 earnings call, investor focus will be on its update pertaining to the progress of studies, evaluating its triple combination regimes for cystic fibrosis.

Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up?

by Zacks Equity Research

During Soleno Therapeutics' (SLNO) Q1 conference call, investor focus will be on its progress with the ongoing study on DCCR tablets, developed for the treatment of Prader-Willi syndrome.

What's in the Cards for Perrigo (PRGO) This Earnings Season?

by Zacks Equity Research

Perrigo (PRGO) is focused on Consumer Healthcare Americas segment. Let's see if it aids the company's results in the soon-to-be reported quarter.

Assertio Therapeutics (ASRT) to Post Q1 Earnings: What's Up?

by Zacks Equity Research

During Assertio Therapeutics' (ASRT) Q1 conference call, investor focus will be on the company's progress with its neurology franchise and the NDA filing for cosyntropin.

Mylan (MYL) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Investors will focus on the performance of Wixela Inhub, the newly launched biosimilars and other updates from Mylan (MYL)'s pipeline when the company shortly reports Q1 results.

What's in Store for Sorrento (SRNE) This Earnings Season?

by Zacks Equity Research

Sorrento (SRNE) may provide update on progress of ZTlido on the first quarter earnings call.

PDL BioPharma (PDLI) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

During PDL BioPharma's (PDLI) Q1 conference call, investor focus will be on the company's ability to acquire new income-generating assets for frequent revenue growth.

Is a Beat in the Cards for Mallinckrodt (MNK) Q1 Earnings?

by Zacks Equity Research

Investors are looking forward to the performance of Specialty Brands and other pipeline updates, when Mallinckrodt (MNK) reports Q1 results on May 7.

AVEO Pharmaceuticals (AVEO) to Post Q1 Earnings: What's Up?

by Zacks Equity Research

During AVEO Pharmaceuticals' (AVEO) Q1 conference call, investor focus will be on its NDA submission for Fotivda in the United States pertaining to the treatment of advanced or metastatic RCC.

What's in the Cards for Bausch Health (BHC) Q1 Earnings?

by Zacks Equity Research

Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q1 results on May 6.

Is a Beat in the Cards for Incyte (INCY) in Q1 Earnings?

by Zacks Equity Research

Incyte (INCY) is slated to report first-quarter results on Apr 30. Investors will primarily focus on Jakafi sales and pipeline updates.

Sangamo (SGMO) Q1 Earnings: What's in Store for the Stock?

by Zacks Equity Research

For Sangamo's (SGMO) Q1, investor focus will be on its gene therapy candidate, SB-525, currently under evaluation for hemophilia A. The company also boasts several other early-stage promising candidates in its pipeline.

Fibrocell (FCSC) Q1 Earnings: What's in Store for the Stock?

by Zacks Equity Research

For Fibrocell's (FCSC) Q1, investors will eye the company's progress with its gene therapy candidate, FCX-007, currently being developed for treating recessive dystrophic epidermolysis bullosa.

5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates

by Zacks Equity Research

So far, the going seems good for the drug/biotech sector this earnings season. Let us take a glance at a few other companies, which hold promise to beat on Q1 earnings.

Is a Beat in the Cards for Molina's (MOH) Earnings in Q1?

by Zacks Equity Research

Molina Healthcare's (MOH) Q1 earnings will gain from membership growth and its streamlining efforts. However, the same might be partially offset by contract losses and the company's Marketplace business.

Universal Health (UHS) Q1 Earnings, Revenues Miss Estimates

by Zacks Equity Research

Universal Health's (UHS) first-quarter earnings are affected by a pre-tax unrealized loss.

What's in Store for HCA Healthcare's (HCA) Q1 Earnings?

by Zacks Equity Research

HCA Healthcare (HCA) is likely to gain from higher admissions. However, escalating expenses might weigh down its margins.